Convalescent Plasma Treatment of Severe COVID-19 A Propensity Score-Matched Control Study

This retrospective, propensity score-matched case control study of 39 patients at a single hospital assessed the effectiveness of convalescent plasma therapy in treating severe or life-threatening COVID-19. The authors found that the proportion of transfused patients with worsened clinical conditions after 14 days was less than the proportion of those who did not receive the therapy. Survival probability was also greater in those who received convalescent plasma.